NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

Show me another pivotal trial in oncology that successfully pivoted off its originally designed primary endpoint, reported a secondary endpoint instead, and then got approval.

I’ll do you one better than just oncology in general, of which there are many examples.

It’s been done for GBM.

That you don’t know that treatments have been approved based on secondary endpoints alone is quite telling.